EP3386541
Vatnskennd lyfjasamsetning sem felur í sér mótefni gegn PD-1, avelúmab
Status:
EP einkaleyfi í gildi á ÍslandiEP appl. date:
5.12.2016EP published:
8.7.2020EP application number:
16818985.0
EP translation filed:
21.9.2020Grant published:
15.10.2020EPO information:
European Patent Register
Max expiry date:
4.12.2036Expiry date:
4.12.2026Next due date:
31.12.2026
Title:
AQUEOUS PHARMACEUTICAL FORMULATION COMPRISING ANTI-PD-1 ANTIBODY AVELUMAB
Timeline
Today
5.12.2016EP application
8.7.2020EP Publication
21.9.2020Translation submitted
15.10.2020Registration published
4.12.2026Expires
Owner
Name:
Merck Patent GmbHAddress:
Frankfurter Strasse 250, 64293 Darmstadt, DE
Name:
Pfizer Inc.Address:
235 East 42nd Street, New York, NY 10017, US
Inventor
Name:
RINALDI, GianlucaAddress:
00015 Monterotondo, IT
Name:
DEL RIO, AlessandraAddress:
00144 Roma, IT
Name:
FRATARCANGELI, SilviaAddress:
03024 Ceprano FR, IT
Name:
VOSS, SentaAddress:
55122 Mainz, DE
Name:
WEIGANDT, MarkusAddress:
68259 Mannheim, DE
Agent
Name:
Árnason Faktor ehf.Address:
Guðríðarstíg 2-4, 113, Reykjavík,
Priority
Number:
15198233Date:
7.12.2015Country:
EP
Classification
Categories:
A61K 39/395, C07K 16/28
Annual fees
Number
Paid
Expires
Payer
Number: 5
Paid: 6.11.2020
Expires: 4.12.2021
Payer: Árnason Faktor ehf.
Number: 6
Paid: 8.11.2021
Expires: 4.12.2022
Payer: Árnason Faktor ehf.
Number: 7
Paid: 9.11.2022
Expires: 4.12.2023
Payer: Árnason Faktor ehf.
Number: 8
Paid: 15.11.2023
Expires: 4.12.2024
Payer: Árnason Faktor ehf.
Number: 9
Paid: 5.11.2024
Expires: 4.12.2025
Payer: Árnason Faktor ehf.
Number: 10
Paid: 5.12.2025
Expires: 4.12.2026
Payer: Árnason Faktor ehf.